DSIP
Nonapeptide · evocative name, thin and contradictory evidence · no receptor
DSIP (delta sleep-inducing peptide) is a textbook example of a famous name resting on surprisingly thin evidence. It is a small nine-amino-acid peptide first isolated in 1977 from the cerebral venous blood of sleeping rabbits, and the evocative name it was given has done far more marketing work than the underlying data ever earned. Nearly fifty years later, no specific DSIP receptor has ever been found, and its natural physiological role and mechanism remain unresolved. The human sleep literature is small, old (clustered in 1981–1987), drawn mostly from a single research group — and openly contradicted within that same period: one independent double-blind study concluded that DSIP's effect on sleep 'is of little clinical significance.' There is no modern large randomized controlled trial establishing it as a sleep medication, it is not approved as a pharmaceutical anywhere, and common vendor claims (a specific half-life, definitive sleep improvement, stress and antioxidant benefits) run ahead of what the primary evidence actually supports. The fair framing is that DSIP is a genuine, well-characterized peptide chemically, with a half-century of scattered research — but its headline 'sleep-inducing' identity is a hypothesis the data never confirmed.
The short version
DSIP stands for 'delta sleep-inducing peptide,' and that name is the most important thing to understand about it — because the name promises far more than the science has ever delivered. It is a tiny peptide, just nine amino acids long, that researchers isolated in 1977 from the blood of rabbits that were in deep ('delta-wave') sleep. The reasoning at the time was that a substance found in the blood during deep sleep might be what induces it. That was a reasonable hypothesis, but it was never firmly confirmed.
The most telling fact is what's missing. After roughly fifty years of study, scientists have never identified a DSIP receptor — the specific docking site a signaling molecule normally uses to produce its effect. Without that, there is no agreed mechanism for how DSIP would actually cause sleep. The literature instead shows a scatter of indirect interactions with various brain chemical systems, none of which adds up to a defined sleep pathway.
And the human evidence is genuinely mixed. A small cluster of studies from the early-to-mid 1980s, mostly from one group, reported sleep improvements in insomniacs — but in the same era, an independent double-blind study concluded the sleep effect was 'of little clinical significance.' There has been no large modern trial to settle it, DSIP is not an approved medicine anywhere, and it is sold only through research-chemical channels. So the honest picture is a well-defined peptide with a famous name, a half-century of inconclusive research, and no established mechanism, dose, or proven sleep benefit in humans.
Molecular identity
Specs
- Molecular weight
- 848.8 g/mol
- Molecular formula
- C₃₅H₄₈N₁₀O₁₅
- Monoisotopic mass
- 848.3301 Da
- CAS / UNII
- 62568-57-4 · YN28Z5YZ73
- Regulatory status
- Research chemical; not FDA-approved
- Sequence
- Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE, 9 AA)PubChem CID 68816; PMID 265572
- Structure / class
- Linear nonapeptide (free acid; INN emideltide)PMID 568769
- Molecular target
- No specific receptor ever identified; mechanism unresolved after ~50 yearsResearch literature
- Half-life
- No validated human pharmacokinetics published (vendor figures unverified)Not established
- Brand / approval
- None — never approved as a drug anywhereResearch literature
Plain English
Mechanism
The central, honest point about DSIP's mechanism is that there isn't an established one. Despite about fifty years of study, no specific DSIP receptor has ever been identified, and its endogenous (natural) physiological role remains poorly characterized. A peptide named for inducing sleep has never been shown to possess a sleep mechanism at the receptor level.
What the literature does contain is a scattering of indirect interactions with neurotransmitter systems — none of which constitutes a defined sleep pathway. Researchers have reported DSIP modulating an enzyme in the rat pineal gland via alpha-adrenergic receptors, influencing somatostatin and growth-hormone release through a dopamine-related mechanism, a proposed serotonin-mediated role in sleep, and a saturable transport system that carries it across the blood–brain barrier. These are fragments, not a coherent model.
Other proposed roles — thermoregulation, stress adaptation, antioxidant or 'adaptive' effects — appear mainly in older, often Russian-language biochemistry work and are best treated as mechanistic hypotheses rather than established pharmacology. Vendor copy presenting DSIP as a defined 'stress' or 'antioxidant' agent is not supported by a coherent primary mechanism. Any specific mechanistic claim about DSIP should be read as unproven.
Sources:PMID 265572PMID 2547200
Why people reach for it
Potential benefits
DSIP is reached for almost entirely for one thing — sleep — but its evidence is thin and openly contradictory, so the honest version keeps the appeal modest. Here's what draws people to it, read against that.
- A reach for deeper, slow-wave sleep — Its whole appeal sits in the name: people use DSIP hoping to deepen delta (slow-wave) sleep. The honest catch — it was named for 1977 rabbit EEG findings, no DSIP receptor or sleep mechanism has ever been established, and the human results are mixed, so this is a why-people-use-it, not a proven effect.
- An on-demand option for rough-sleep nights — Because it's dosed acutely before bed rather than built up over weeks, some reach for it situationally — a bad-sleep night, travel, jet-lag recovery — rather than running it continuously.
- A short, well-characterized peptide chemically — Whatever the sleep question, DSIP itself is a genuine, well-defined nonapeptide with a half-century of (scattered) research behind it — the chemistry is solid even where the sleep claim isn't.
- The honest counterweight — the evidence is genuinely contested — DSIP is approved nowhere, has no validated dose, and its most rigorous human study concluded the sleep effect was 'of little clinical significance.' Vendor claims of a fixed half-life or stress/antioxidant benefits run ahead of the primary data — and behavioural sleep hygiene is the better-proven lever.
Sources:PMID 265572PMID 3583493PMID 6112579
What people reach for DSIP for, drawn from what the research reports (small, old, and contradictory) and how it's used — not proven outcomes or any claim that it treats insomnia.
Implied timing
Best time to dose
Implied best time
Bedtime
DSIP is taken 30–60 minutes before sleep — the clearest timing verdict in this library, because it's used as a sleep peptide.
- Its entire proposed job is to act on delta (slow-wave) sleep architecture, so dosing in the approach to sleep — 30–60 minutes before intended sleep onset — is the only timing that fits the intended effect. This is the community convention and the obvious one.
- It's dosed acutely right before bed, not as a long-acting depot, so unlike most peptides there's no daytime or split-dose pattern to weigh — bedtime is the whole window.
- Daytime dosing would make no sense for a sleep-targeting compound; the timing here isn't a compromise between options, it's dictated directly by the goal.
- Practical note: there's no validated human half-life for DSIP, so the 30–60-minute pre-sleep window is reasoned from how a sleep peptide is used, not from a measured PK curve.
No study establishes a precise ideal time for DSIP — but unlike the rest of the library, this one isn't a midday-to-evening judgment call. As a sleep-targeting peptide it's the clear bedtime exception: taken 30–60 minutes before sleep, reasoned directly from its proposed delta-sleep role and how it's used.
How to run it
Dosing & protocol
DSIP is injected subcutaneously — that is the route in the historical human literature and the form the on-page calculator is built for. There is no validated human dose. The community convention (500–1,000 mcg before bed) is extrapolated from the older study literature and the peptide's proposed sleep-promoting job, not from a dose-finding trial. The Monti 1987 double-blind study — the most rigorous entry in the literature — concluded DSIP's sleep effect was 'of little clinical significance.' Read every number here as what users have settled on in practice, not as a proven effective dose.
Community convention only, not trial-proven: DSIP has no modern RCT, no FDA approval, no validated human dose, and its mechanism is unresolved after ~50 years. The only dose firmly tied to a primary study produced a clinically insignificant result. Numbers below are usage patterns, not evidence.
Tiered dose ranges
Convention doses are expressed in mcg and scaled to goal — lower end for general sleep support, upper end for acute insomnia nights.
- Lower / exploratory:
- 500 mcg subcutaneously before bed — the starting range; lets you gauge response on a peptide with no established dose.
- Standard:
- 750–1,000 mcg subcutaneously before bed — the most commonly referenced community range for ongoing sleep-quality goals.
- Upper convention:
- Up to 1,000 mcg once nightly — staying within the range referenced in older literature; no evidence supports going higher and no human ceiling dose has been established.
Subcutaneous administration
DSIP is injected into subcutaneous fat ~30 minutes before intended sleep onset; site, timing, and food window are the actionable choices.
- Injection site:
- Abdomen (a couple of inches from the navel), love-handle area, or outer thigh. Rotate sites across uses to prevent local irritation.
- Measuring the dose:
- Drawn on a U-100 insulin syringe from the reconstituted vial; the reconstitution card below gives syringe units at the standard 10 mg / 2 mL mix. The on-page calculator handles any vial size.
- Timing:
- 30–60 minutes before intended sleep — DSIP is proposed to act on delta-sleep architecture, so injecting in the approach to sleep is the community convention. No food-window restriction applies for subcutaneous use.
- Food window:
- No interaction with food; subcutaneous DSIP can be injected independent of the last meal.
Cycle & washout
Given the thin evidence base, shorter cycles and observation periods are the pragmatic convention.
- Typical cycle:
- 2–4 weeks of nightly use, then assess whether sleep quality has changed. Some users run it only on nights with anticipated poor sleep rather than daily.
- Washout:
- 1–2 weeks off between cycles. No receptor-saturation mechanism is established for DSIP (no receptor has been found), so washout logic is precautionary rather than pharmacologically mandated.
- On-demand use:
- Because DSIP is acutely dosed (not a long-half-life depot), some users treat it as situational — pre-travel, acute insomnia nights, jet-lag recovery — rather than running a fixed daily cycle.
Reconstitution at a glance
The on-page calculator does this live; quick reference for the default 10 mg vial + 2 mL bacteriostatic water:
- Mixing:
- 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg per mL. On a 100-unit (1 mL) U-100 insulin syringe: 500 mcg = 10 IU · 750 mcg = 15 IU · 1,000 mcg = 20 IU.
- Why 2 mL:
- Keeps dose volumes in a practical syringe range (10–20 IU) so small microgram amounts are measurable without microscopic increments.
Substrate the signal needs
Nutritional cofactor precision
DSIP's proposed job is to deepen slow-wave (delta) sleep. The useful cofactors either amplify the same wind-down biology from a different angle, or supply the raw materials sleep architecture runs on. The critical honesty point: behavioural sleep hygiene is the actually-proven lever here — consistent timing, darkness, and a cool room do more for deep sleep than any peptide or supplement. Everything below is a support layer around that foundation, not a substitute for it.
Reasoned from sleep neurobiology and DSIP's proposed delta-sleep angle — not a DSIP cofactor study (none exists). Supplement doses are established community ranges for sleep support, not DSIP-specific findings. DSIP's own sleep mechanism is unresolved; these cofactors support sleep on their own terms.
Sleep hygiene — the proven lever
The single most evidence-backed sleep intervention is not a compound. Lead with this; the peptide and supplements below are speculative additions on top of it.
- Consistent sleep/wake timing:
- Going to bed and waking at the same time every day — including weekends — is the most robustly proven driver of sleep quality and delta-sleep depth. Irregular timing disrupts circadian entrainment in ways no peptide compensates for.
- Light and dark control:
- Bright light in the morning (10–30 min outdoor or bright-lamp exposure) anchors the circadian clock; no bright screens or overhead lighting for 60–90 min before bed. Melatonin suppression by light at night directly blunts delta-sleep onset.
- Sleep environment:
- A cool room (around 65–68 °F / 18–20 °C), complete darkness, and quiet. Core body temperature drop is a primary trigger of slow-wave sleep; heat and light directly suppress it.
Magnesium glycinate + glycine — relaxation substrate
Two overlapping wind-down compounds that support GABA-mediated calm and lower core body temperature — the same physiology DSIP is proposed to nudge.
- Mechanism:
- Magnesium is an NMDA-receptor antagonist and GABA potentiator — dietary deficiency is common and associated with light, fragmented sleep. Glycine (a conditionally essential amino acid) lowers core body temperature slightly and has been shown in human trials to improve sleep onset and next-day alertness. These act on their own; the rationale for combining them with DSIP is that they address the same delta-sleep window from the nutrition side.
- Dose & timing:
- Magnesium glycinate 300–400 mg + glycine 3 g, taken 30–60 minutes before bed — matching the timing of the DSIP injection.
Tryptophan pathway — melatonin substrate
The body's own night-signal (melatonin) is built from dietary tryptophan via serotonin; supporting this chain is basic sleep neurobiology.
- Mechanism:
- Tryptophan → 5-HTP → serotonin → melatonin is the endogenous synthesis chain. Vitamin B6 (pyridoxal-5-phosphate) is the rate-limiting cofactor for the last conversion. L-tryptophan or 5-HTP at the right dose raises evening serotonin and melatonin availability. Low-dose melatonin (0.3–1 mg) can be used directly to signal circadian 'night' onset — particularly useful for jet lag or shift-work disruption — without the dose-dependent blunting seen at the common 5–10 mg OTC doses.
- Dose & timing:
- L-tryptophan 500–1,000 mg or 5-HTP 50–100 mg with dinner, or melatonin 0.3–1 mg 30 min before bed. Do not combine 5-HTP with SSRIs or other serotonergic agents without medical guidance.
Combinations + timing
Stacking notes + timing windows
DSIP is proposed to act on delta-sleep architecture via an unresolved mechanism — no specific receptor has been identified. Any stack below is reasoned from complementary sleep levers (circadian vs. sleep-architecture vs. stress-buffer), not from a studied combination. Because DSIP's own effect is unproven and its mechanism unknown, every stack here is doubly unproven: a reasoned guess on top of a contested foundation. Flag this honestly and stack conservatively.
User combinations reasoned from complementary mechanisms — not head-to-head studied, and DSIP itself has no modern RCT. Doses are community convention. 'Commonly combined for' describes where users reach, not a proven indication.
DSIP + Epitalon
The circadian-angle partner: Epitalon works on the pineal gland to restore melatonin rhythm, which is a different lever from DSIP's proposed delta-sleep deepening.
- Why it works:
- Epitalon (Ala-Glu-Asp-Gly, a tetrapeptide) is proposed to restore pineal melatonin secretion — addressing the circadian timing and melatonin-production side of sleep. DSIP is proposed to act on slow-wave sleep depth. Two different proposed angles: circadian entrainment vs. sleep-architecture depth — not the same lever twice. That said, both mechanisms are unresolved, so the synergy is reasoned, not demonstrated.
- The protocol:
- DSIP 500–1,000 mcg subcutaneously before bed, on nightly use; Epitalon on its own typical short-course cycle (commonly 10–20 days at 5–10 mg/day SubQ, run as a separate course rather than co-injected nightly). The two are not typically co-injected but run as sequential or overlapping cycles.
- Outcome:
- Commonly combined for age-related sleep disruption and circadian misalignment — the rationale being that ageing blunts both pineal melatonin output (Epitalon's proposed target) and delta-sleep depth (DSIP's proposed target). Note: both mechanisms are contested; treat as complementary bets, not confirmed synergy.
Reconstitution math
Reconstitution calculator
Reconstitution calculator
Calculated for a 1 mL U-100 insulin syringe (100 units/mL).
Units per dose
20
Draw to this mark on a U-100 syringe
- Volume per dose
- 0.2 mL
- Doses per vial
- 10
- Concentration
- 5 mg/mL
One vial lasts
- Daily
- 10 days
- Every other day
- 20 days
- 5×/week
- 14 days
Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.
From the studies
Side effects from research
Safety information for DSIP is limited and dated, coming chiefly from small 1980s studies, with no modern systematic safety surveillance and no large or long-term human safety dataset.
The pilot and clinical studies of that era (in pain and in withdrawal) did not report DSIP as overtly toxic at the doses used, but their small size and the absence of modern pharmacovigilance mean the real-world safety profile is effectively uncharacterized — especially for current 'research chemical' use that bears little resemblance to a controlled study.
Gray-market sourcing adds purity and identity risk independent of the peptide itself. The honest summary is that DSIP's safety is poorly characterized rather than established as benign.
As reported in literature
Research dosing ranges
These are doses from older studies, shown for reference only — there is no validated human regimen. The single most important entry is the double-blind study that found DSIP's sleep effect clinically insignificant, because it directly contradicts the marketing narrative. Note how the human literature pits a single group's positive reports against an independent null-significance result, with no modern trial to resolve it.
| Dose | Route | Model | Outcome | Sources: |
|---|---|---|---|---|
| Brain infusion | ICV | Rabbit — original isolation/characterization (1977) | Synthetic DSIP enhanced delta and spindle EEG patterns in rabbits — the basis for the name (animal EEG, not human sleep) | PMID 265572 |
| 25 nmol/kg | IV | Human RCT — double-blind crossover, chronic insomniacs (Monti 1987) | Some statistical changes vs baseline, but the authors concluded sleep improvement 'is of little clinical significance' — the key contradiction | PMID 3583493 |
| Parenteral (1980s) | IV / SC | Human — insomnia reports, Schneider-Helmert group (Lancet 1981, Eur Neurol 1986) | Reported improved sleep in insomniacs, but mostly from one group and not independently replicated; the Lancet record has no abstract to quantify the claim | PMID 6112579 |
| Pilot dosing | Parenteral | Human — chronic pain pilot study (Larbig 1984) | Reported benefit on pronounced pain episodes, but explicitly a small uncontrolled pilot — not confirmatory | PMID 6548970 |
Quick answers
Frequently asked
Does DSIP actually induce sleep?
The evidence does not clearly show that it does in humans. Its name comes from 1977 rabbit experiments linking it to deep-sleep brain waves, but no DSIP receptor or sleep mechanism has ever been established. Human studies are small, old, and contradictory — one independent double-blind study concluded the sleep effect was 'of little clinical significance.'
Is there a known mechanism?
No. After roughly fifty years, no specific DSIP receptor has been identified and there is no agreed mechanism of action. The literature shows only scattered, indirect interactions with various neurotransmitter systems — not a defined sleep pathway.
Is DSIP approved or proven as a sleep aid?
No. DSIP is not approved as a pharmaceutical anywhere, has no pharmacopoeial monograph or validated human dose, and there is no modern large randomized controlled trial establishing it as a sleep medication. It is sold only through research-chemical channels.
What dose is used?
There is no validated human dose. The one dose tied firmly to a primary study is 25 nmol/kg given intravenously in a 1980s double-blind trial — and that study found the result clinically insignificant. Specific microgram doses quoted by vendors could not be traced to a named primary study and should be treated as unverified.
Is DSIP banned in sport?
It is not specifically named on the 2026 WADA Prohibited List, including the peptide-hormones section (S2). However, the list's catch-all language for related or non-approved substances could plausibly capture an unapproved injectable neuropeptide, so 'not named' should not be read as 'permitted.' Athletes should verify against the official WADA list and consult their anti-doping authority.
Primary sources
References
- PMID 265572Schoenenberger & Monnier, PNAS 1977 — original isolation/characterization of the delta-EEG-inducing nonapeptide (rabbit)
- PMID 568769Schoenenberger et al., Pflugers Arch 1978 — amino-acid analysis, sequence, synthesis of the nonapeptide
- PMID 3583493Monti et al., Int J Clin Pharmacol Res 1987 — double-blind crossover; sleep effect 'of little clinical significance'
- PMID 6112579Schneider-Helmert et al., Lancet 1981 — 'synthetic DSIP improves sleep in insomniacs' (no abstract on record)
- PMID 6548970Larbig et al., Eur Neurol 1984 — chronic-pain clinical pilot study
- PMID 6548969Dick et al., Eur Neurol 1984 — DSIP in alcohol/opiate withdrawal syndromes
- PMID 2547200Zlokovic et al., Peptides 1989 — saturable blood-brain-barrier transport mechanism
- PubChem CID 68816PubChem record — identity (CID, formula, MW, CAS, sequence)
- WADA 2026WADA 2026 Prohibited List (DSIP not individually named; status by inference)
Research use only · Not medical advice · Updated 2026-06-01